BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23567933)

  • 1. A3 adenosine receptor: homology modeling and 3D-QSAR studies.
    Almerico AM; Tutone M; Pantano L; Lauria A
    J Mol Graph Model; 2013 May; 42():60-72. PubMed ID: 23567933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linear and nonlinear 3D-QSAR approaches in tandem with ligand-based homology modeling as a computational strategy to depict the pyrazolo-triazolo-pyrimidine antagonists binding site of the human adenosine A2A receptor.
    Michielan L; Bacilieri M; Schiesaro A; Bolcato C; Pastorin G; Spalluto G; Cacciari B; Klotz KN; Kaseda C; Moro S
    J Chem Inf Model; 2008 Feb; 48(2):350-63. PubMed ID: 18215030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affinity prediction on A3 adenosine receptor antagonists: the chemometric approach.
    Luan F; Melo A; Borges F; Cordeiro MN
    Bioorg Med Chem; 2011 Nov; 19(22):6853-9. PubMed ID: 21992803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A
    Poli D; Falsini M; Varano F; Betti M; Varani K; Vincenzi F; Pugliese AM; Pedata F; Dal Ben D; Thomas A; Palchetti I; Bettazzi F; Catarzi D; Colotta V
    Eur J Med Chem; 2017 Jan; 125():611-628. PubMed ID: 27721147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scaffold decoration at positions 5 and 8 of 1,2,4-triazolo[1,5-c]pyrimidines to explore the antagonist profiling on adenosine receptors: a preliminary structure-activity relationship study.
    Federico S; Ciancetta A; Porta N; Redenti S; Pastorin G; Cacciari B; Klotz KN; Moro S; Spalluto G
    J Med Chem; 2014 Jul; 57(14):6210-25. PubMed ID: 24972108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition.
    Lenzi O; Colotta V; Catarzi D; Varano F; Poli D; Filacchioni G; Varani K; Vincenzi F; Borea PA; Paoletta S; Morizzo E; Moro S
    J Med Chem; 2009 Dec; 52(23):7640-52. PubMed ID: 19743865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular modeling study on potent and selective adenosine A(3) receptor agonists.
    Dal Ben D; Buccioni M; Lambertucci C; Marucci G; Thomas A; Volpini R; Cristalli G
    Bioorg Med Chem; 2010 Nov; 18(22):7923-30. PubMed ID: 20943397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular modeling of adenosine receptors.
    Martinelli A; Ortore G
    Methods Enzymol; 2013; 522():37-59. PubMed ID: 23374179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation.
    Squarcialupi L; Colotta V; Catarzi D; Varano F; Filacchioni G; Varani K; Corciulo C; Vincenzi F; Borea PA; Ghelardini C; Di Cesare Mannelli L; Ciancetta A; Moro S
    J Med Chem; 2013 Mar; 56(6):2256-69. PubMed ID: 23427825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QSAR of adenosine receptor antagonists: Exploring physicochemical requirements for binding of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives with human adenosine A(3) receptor subtype.
    Pran Kishore D; Balakumar C; Raghuram Rao A; Roy PP; Roy K
    Bioorg Med Chem Lett; 2011 Jan; 21(2):818-23. PubMed ID: 21163647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists.
    Da Settimo F; Primofiore G; Taliani S; Marini AM; La Motta C; Simorini F; Salerno S; Sergianni V; Tuccinardi T; Martinelli A; Cosimelli B; Greco G; Novellino E; Ciampi O; Trincavelli ML; Martini C
    J Med Chem; 2007 Nov; 50(23):5676-84. PubMed ID: 17927167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites.
    Michielan L; Bolcato C; Federico S; Cacciari B; Bacilieri M; Klotz KN; Kachler S; Pastorin G; Cardin R; Sperduti A; Spalluto G; Moro S
    Bioorg Med Chem; 2009 Jul; 17(14):5259-74. PubMed ID: 19501513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives.
    Catarzi D; Colotta V; Varano F; Lenzi O; Filacchioni G; Trincavelli L; Martini C; Montopoli C; Moro S
    J Med Chem; 2005 Dec; 48(25):7932-45. PubMed ID: 16335918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting a receptor-based pharmacophore hypothesis for human A(2A) adenosine receptor antagonists.
    Bacilieri M; Ciancetta A; Paoletta S; Federico S; Cosconati S; Cacciari B; Taliani S; Da Settimo F; Novellino E; Klotz KN; Spalluto G; Moro S
    J Chem Inf Model; 2013 Jul; 53(7):1620-37. PubMed ID: 23705857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.
    Pastorin G; Da Ros T; Bolcato C; Montopoli C; Moro S; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
    J Med Chem; 2006 Mar; 49(5):1720-9. PubMed ID: 16509587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterisation of novel adenosine A
    Barkan K; Lagarias P; Stampelou M; Stamatis D; Hoare S; Safitri D; Klotz KN; Vrontaki E; Kolocouris A; Ladds G
    Sci Rep; 2020 Nov; 10(1):20781. PubMed ID: 33247159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topological sub-structural molecular design (TOPS-MODE): a useful tool to explore key fragments of human A3 adenosine receptor ligands.
    Saíz-Urra L; Teijeira M; Rivero-Buceta V; Helguera AM; Celeiro M; Terán MC; Besada P; Borges F
    Mol Divers; 2016 Feb; 20(1):55-76. PubMed ID: 26205409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation.
    Varano F; Catarzi D; Squarcialupi L; Betti M; Vincenzi F; Ravani A; Varani K; Dal Ben D; Thomas A; Volpini R; Colotta V
    Eur J Med Chem; 2015; 96():105-21. PubMed ID: 25874336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Taxicab geometry quantification system to evaluate the performance of in silico methods: a case study on adenosine receptors ligands.
    Kuder KJ; Michalik I; Kieć-Kononowicz K; Kolb P
    J Comput Aided Mol Des; 2020 Jun; 34(6):697-707. PubMed ID: 32112287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances on A₃ adenosine receptor antagonists by QSAR tools.
    Luan F; Borges F; Cordeiro MN
    Curr Top Med Chem; 2012; 12(8):878-94. PubMed ID: 22352915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.